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Abstract
The innate immune response provides the first line of defense against viruses and other pathogens by responding to
specific microbial molecules. Influenza A virus (IAV) produces double-stranded RNA as an intermediate during the
replication life cycle, which activates the intracellular pathogen recognition receptor RIG-I and induces the production of
proinflammatory cytokines and antiviral interferon. Understanding the mechanisms that regulate innate immune responses
to IAV and other viruses is of key importance to develop novel therapeutic strategies. Here we used myeloid cell specific
A20 knockout mice to examine the role of the ubiquitin-editing protein A20 in the response of myeloid cells to IAV
infection. A20 deficient macrophages were hyperresponsive to double stranded RNA and IAV infection, as illustrated by
enhanced NF-kB and IRF3 activation, concomitant with increased production of proinflammatory cytokines, chemokines
and type I interferon. In vivo this was associated with an increased number of alveolar macrophages and neutrophils in the
lungs of IAV infected mice. Surprisingly, myeloid cell specific A20 knockout mice are protected against lethal IAV infection.
These results challenge the general belief that an excessive host proinflammatory response is associated with IAV-induced
lethality, and suggest that under certain conditions inhibition of A20 might be of interest in the management of IAV
infections.
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Introduction
Viruses are a class of highly diverse pathogens which depend on
the host cell for their replication. The initiation of a protective
innate antiviral immune response involves the action of specialized
pattern recognition receptors (PRR), which detect conserved
molecular structures of the invading pathogen. Triggering of
PRRs induces the production of host proinflammatory cytokines
(e.g. TNF, IL-6 and IL-1) and type I interferons (interferon-a
(IFN-a) and IFN-b) through activation of downstream signaling
pathways that control various transcription factors such as NF-kB,
AP-1, IRF3 and IRF7 [1,2]. The presence of viral nucleic acids,
such as viral RNA and DNA, viral replication intermediates and
viral transcription products, can be sensed by specific intracellular
PRRs [3]. Endosomal Toll-like receptors (TLRs) and cytoplasmic
RNA helicase RIG-I-like receptors (RLRs) or Nod-like receptors
(NLRs) detect the presence of viral single stranded (TLR7, TLR8,
Nod2) or double stranded RNA (TLR3, RIG-I, MDA5).
Intracellular DNA sensors that mediate antiviral immune
responses to DNA viruses include TLR9, DAI [4] and the PYHIN
domain containing proteins AIM2 [5,6,7] and IFI16 [8]. TLR
mediated antiviral responses are restricted to specialized type I
IFN producing plasmacytoid dendritic cells (pDC), while most
other cell types, including conventional DC (cDC), macrophages
and fibroblasts, depend on the cytosolic RNA and DNA sensors
for the production of antiviral proteins [9].
Influenza A virus (IAV) is the etiological agent of a contagious
acute respiratory disease that causes considerable mortality, which
is generally believed to be due to an excessive host inflammatory
response. Emergence of drug-resistant strains of influenza viruses
with pandemic potential underscores the importance of developing
novel antiviral strategies. In this context, understanding of the
mechanisms that regulate IAV-induced immune responses is
critical. IAV infection leads to the exposure in the host cell of
single-stranded genomic RNA and double stranded RNA, the
latter being an intermediate of viral replication. TLR3 and RIG-I
have been implicated as sensors of IAV infection [10–12]. Both
receptors contribute to the proinflammatory response to IAV, but
the initiation of the innate antiviral immune response largely
depends on RIG-I mediated signaling [13]. Interestingly, RIG-I
PLoS Pathogens | www.plospathogens.org 1 March 2012 | Volume 8 | Issue 3 | e1002570deficient mice are highly susceptible to IAV [14,15], whereas
TLR3 deficient mice have a survival advantage to acute infection
[16]. These results indicate that an imbalance between the
beneficial and harmful effects of mediators released by immune
cells is likely to contribute to the pathogenesis of influenza.
RIG-I contains a C-terminal DExD/H box helicase domain,
which is required for ligand recognition, and two N-terminal
CARD domains. Upon ligand binding, the CARD domains of
RIG-I associate with the CARD domain of the MAVS (also
termed IPS-1, VISA, Cardif) adaptor protein, which subsequently
translocates to and inserts in the outer mitochondrial membrane
via its C-terminal transmembrane domain [17–20]. Signaling
downstream of MAVS requires the action of various ubiquitin
modifying enzymes, which both positively and negatively regulate
RIG-I mediated signal transduction [21]. K63-specific ubiquitin
ligases (E3s), such as TRIM25 [22] and Riplet [23,24], have been
shown to directly promote RIG-I activation. In addition, well
characterized ubiquitin ligases such as TRAF6 [25,26] and
TRAF3 [27] mediate respectively NF-kB and IRF3 activation
upon RIG-I stimulation. On the other hand, deubiquitinating
enzymes (DUBs), such as DUBA [28], CYLD [29,30] and
OTUB1/2 [31] have been shown to negatively regulate RLR
signaling by specifically removing K63-linked polyubiquitin chains
from several signaling molecules. Furthermore, various K48-
specific ubiquitin ligases, such as AIP4 [32] and TRIAD3A [33]
mark respectively MAVS and TRAF3 for proteasome mediated
degradation, thus inhibiting further downstream signaling. Addi-
tionally, the attachment of K48-specific polyubiquitin chains to the
IRF3 and IRF7 transcription factors by E3s such as RAUL [34],
TRIM21 [35] and RBCK1 [36] further dampens antiviral signal
transduction.
A20 is an ubiquitin-editing enzyme belonging to the OTU-
domain family of DUBs. Interestingly, A20 also harbors atypical
zinc finger dependent K48-specific E3 ubiquitin ligase activity.
Both catalytic and noncatalytic mechanisms were previously
shown to be involved in the negative regulation of proinflamma-
tory signaling by A20 in response to multiple receptors such
as TNF receptor I [37–39], TLR4 [40], and IL-1R [41]. The
anti-inflammatory role of A20 is clearly demonstrated by the fact
that A20 deficient mice die early after birth due to severe multi-
organ inflammation and cachexia [37]. More recently, gene
targeting of A20 in specific cell types was shown to be associated
with autoimmunity and chronic inflammation [42–48], further
illustrating that A20 is an important brake on the inflammatory
response. The relevance of these findings for human disease has
recently been illustrated through the identification of polymor-
phisms in the A20 locus that are associated with several
autoimmune diseases and chronic inflammation [45]. In contrast
to its well established function in the regulation of proinflamma-
tory responses, the role of A20 in the regulation of antiviral
immune responses is less well described and limited to a number of
in vitro studies using overexpression or silencing in specific cell lines,
indicating that A20 may regulate RIG-I- and TLR3-induced
signaling to NF-kB and IRF-3 [49–52]. However, the precise in
vivo role of A20 in the response to viral infection remains to be
clarified. Using myeloid cell specific A20 knockout mice (A20
myel-
KO) that were recently generated in our lab and primary cells
derived of these mice, we here provide evidence that A20 is a
crucial negative regulator of IAV-induced proinflammatory and
antiviral signaling in macrophages. Interestingly, A20
myel-KO mice
show enhanced survival and reduced morbidity in response to IAV
lung infection compared to wild type mice. Protection against IAV
in A20
myel-KO mice is associated with increased cytokine and
chemokine production, augmented recruitment of innate immune
cells such as neutophils and alveolar macrophages, and enhanced
viral clearance. These results suggest that boosting the innate
immune response to IAV by targeting A20 activity in myeloid cells
might have therapeutic potential.
Results
A20 inhibits RIG-I-induced NF-kB and IRF3 activation
RIG-I signaling induces the activation of NF-kB, IRF3 and
IRF7 transcription factors, which promote the expression of
proinflammatory cytokines and type I IFNs that restrict further
viral propagation. Previous studies have shown that ectopically
expressed A20 negatively regulates NF-kB and IRF3 activation
upon RIG-I stimulation [50–52]. Similarly, we show that A20
overexpression in HEK293T cells prevents NF-kB- and IRF3-
dependent luciferase reporter gene activation induced by trans-
fection of a truncated constitutive active form of RIG-I [53],
corresponding to only the two N-terminal CARD domains of
RIG-I [RIG-I (2CARD)] (figure 1A, left and middle graph). We
next investigated whether A20 also inhibits IRF7 activation.
Unlike IRF3, IRF7 is not or weakly expressed under naı ¨ve
conditions and IRF7 protein levels are rapidly upregulated upon
virus-induced IRF3 activation [54,55]. To determine the effect of
A20 on IRF7 activation, we therefore transfected minor amounts
of an IRF7 expression plasmid together with plasmids encoding
RIG-I (2CARD), A20 and an IRF7-specific IFNa4 luciferase
reporter construct. RIG-I (2CARD) expression in the absence of
IRF7 co-expression showed negligible IFNa4 promoter activation
(grey bar, figure 1A, right graph), whereas significant reporter gene
expression was observed in the presence of IRF7. Similar to its
inhibitory effect on NF-kB and IRF3 activation, A20 also
prevented RIG-I-induced IRF7 activation (figure 1A, right graph).
These results demonstrate the potential of A20 to inhibit RIG-I-
induced NF-kB and IRF3/7 activation.
To study the effect of endogenously expressed A20 on RIG-I-
induced signaling in a more immunological relevant context, we
performed further experiments in A20 deficient primary macro-
phages. Since A20 full knockout mice die prematurely as a result of
Author Summary
Influenza virus or flu epidemics represent a recurrent
threat to the public health, especially for individuals which
are part of a high-risk group such as children, elderly or
immune-compromised people. Sporadic pandemic flu
outbreaks, such as the Spanish flu of 1918, may cause
high grades of mortality among healthy persons. A better
understanding of how the immune system deals with
these pathogens is of key importance. The protein A20 is
an important negative regulator of both innate and
adaptive immune responses. We show that the specific
deletion of A20 in myeloid cells, such as macrophages and
neutrophils, improves the resistance against otherwise
lethal influenza infections. This protective effect is
mediated by an enhanced innate immune response
following respiratory challenge with influenza virus.
Although exaggerated pulmonary immune responses are
believed to be the primary cause of often life threatening
influenza virus induced pneumonia, we demonstrate that
boosting the innate immune response by selectively
targeting the functionality of A20 in myeloid cells is
beneficial for the host survival. This finding provides us
with a novel valuable approach for treating influenza and
potentially other respiratory viral infections.
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a conditional A20 allele in which exon IV and exon V were
flanked by two loxP sites [56]. Crossing these mice with transgenic
mice expressing Cre recombinase under control of the lysozyme M
promoter leads to specific deletion in myeloid cells and allowed us
to generate myeloid cell specific A20 knockout mice [48]. To
stimulate the RIG-I receptor, we transfected A20
myel-KO BMDM
and wild type control cells with minimal amounts of low molecular
Figure 1. A20 inhibits NF-kB and IRF3 activation in response to RIG-I stimulation. (A) HEK293T cells were transfected with NF-kB (left), IRF3
(middle) or IRF7 dependent luciferase reporter (right) plasmids, together with plasmids expressing RIG-I (2CARD), IRF7 (right) and increasing amounts
of A20. Luciferase activity in cell extracts was analyzed in a luminometer. Numbers are averages +/2 SD of 3 samples per set-up. (B–D) A20
myel-KO and
wild type (A20
myel-WT) BMDM were transfected with LMW poly(I:C) and analyzed at different time points (minutes) after the start of transfection for
IkBa phosphorylation and degradation, and IRF3 phosphorylation by immunoblotting of total cell extracts (B). The band that is non-specifically
recognized by the anti-IkBa antibody (indicated by an asterisk) can be used as a loading control. Nuclear translocation of NF-kB (p65) and IRF3 was
analyzed by immunoblotting of cytoplasmic or nuclear fractions (C). Quantification of band density for nuclear p65 and IRF3 is shown in bar graphs
(expressed as relative density compared to the first lane; =time 0). IL-6, TNF and IFNb levels in the supernatant of cells used in (B) were determined
by bioassay (IL-6) and ELISA (TNF and IFNb) as described in the ‘materials and methods’ section (D). Data are representative of 2 independent
experiments.
doi:10.1371/journal.ppat.1002570.g001
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and activate RIG-I rather than MDA5 [57]. Of note, this
concentration of poly(I:C) was unable to induce significant
TLR3 dependent NF-kB and IRF3 activation or cytokine
production (data not shown). As expected, poly(I:C) transfection
induced the rapid expression of A20 in wild type, but not in
A20
myel-KO BMDM (figure 1B, upper panel). At early time
points, slightly slower migrating forms of A20 were observed,
indicating that A20 undergoes a yet unknown modification
upon poly(I:C) transfection. Compared to wild type BMBM,
A20 deficient cells showed enhanced NF-kB activation as
indicated by increased phosphorylation and sustained degrada-
tion of IkBa (figure 1B). Furthermore, nuclear translocation of
the p65 NF-kB subunit was enhanced in poly(I:C) transfected
A20
myel-KO BMDM, reaching a maximum at earlier time points
compared to wild type cells (figure 1C). IRF3 is known to be
activated upon phosphorylation of a series of carboxyl terminal
serine residues by the IKK-like kinases TBK1 and IKKe [58],
leading to its dimerization and subsequent translocation to the
nucleus [59]. Using immunoblotting with an antibody directed
against phosphorylated Ser396, maximum IRF3 phosphoryla-
tion was detected at earlier time points in A20
myel-KO BMDM
compared to wild type BMDM (figure 1B). Similar to p65, IRF3
nuclear translocation reached its maximum at an earlier time
point in A20 deficient BMDM compared to wild type cells
(figure 1C). NF-kB controls the expression of IL-6 and TNF,
and NF-kB and IRF3 control the expression of IFNb.I nl i n e
with the enhanced activation of NF-kB and IRF3 as described
above, A20
myel-KO BMDM secreted increased amounts of IL-6,
TNF and IFNb (figure 1D). Similar results were obtained using
peritoneal macrophages (data not shown). Together, these
results demonstrate that A20 plays an important role in the
negative regulation of RIG-I-induced NF-kBa n dI R F 3
activation in primary macrophages.
A20 negatively regulates IAV-induced gene expression in
BMDM
To investigate the role of A20 in the IAV-induced proin-
flammatory and antiviral innate immune responses, we infected
A20 deficient and control BMDM with IAV X-47 (H3N2). A20
mRNA levels were rapidly induced in wild type BMDM, but not
in A20 deficient BMDM, upon viral infection (figure 2A).
Furthermore, A20
myel-KO BMDM show enhanced expression of
IL-6 and IFNb mRNA after IAV infection compared to control
cells (figure 2A). In accordance with these data, cell culture
supernatant collected from these cells contained higher levels of
TNF and IFNb (figure 2B).
Upon host infection with IAV, alveolar macrophages are an
important source of cytokines and chemokines, attracting innate
immune cells to the lung during the primary phase of infection.
To test whether A20 directly controls IAV-induced gene
expression in alveolar macrophages, we isolated these cells
from lungs of A20
myel-KO and control littermates and infected
them in vitro with IAV X-47. Expression and secretion of the
proinflammatory cytokines IL-6 and TNF, the type-I IFN IFNb
and IFNa4 and the chemokines MCP-1 (ccl2) and KC (cxcl1)
was significantly higher in IAV infected cells lacking A20
compared to infected wild type cells (figure 2C and figure S1).
Figure 2. A20 negatively regulates IAV-induced gene expression in BMDM and alveolar macrophages. (A–B) BMDM isolated from
A20
myel-WT and A20
myel-KO animals were infected with IAV (moi 1). At different hours post infection (hours p.i.) cells were lysed and IL-6, IFNb and A20
mRNA expression was analyzed by qPCR (A). 18 hours post infection cell culture supernatant was analyzed for TNF and IFNb protein levels by ELISA
and multiplexing technologies (B). (C–D) Alveolar macrophages were mock treated or infected with IAV (moi 1) for 18 hours. IL-6 and IFNb mRNA
expression was determined by qPCR (C). Cell culture supernatant was analyzed for IL-6 and IFNb protein levels by ELISA and multiplexing
technologies (D). Error bars represent mean values (+/2 SEM) of 2–3 samples. Results are representative for 2 independent experiments. ***p,0,001.
doi:10.1371/journal.ppat.1002570.g002
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regulates IAV-induced proinflammatory and antiviral gene expres-
sion in alveolar macrophages, consistent with the inhibitory effect of
A20 seen on RIG-I-induced NF-kB and IRF3 activation.
A20 deficiency in myeloid cells protects against IAV lung
infection
To determine the role of A20 expression in myeloid cells during
an IAV infection in vivo, we intranasally inoculated both A20
myel-
KO mice and control littermates with a sublethal dose of the mouse
adapted IAV X-47 (H3N2) strain and monitored morbidity in
terms of weight loss. A20
myel-KO mice showed reduced weight loss
compared to wild type control littermates and recovered faster
from the viral challenge (figure 3A). Also, total protein concen-
tration in BAL fluid, which reflects lung damage and vascular
leakage, was increased significantly at 7 and 10 days post infection
in both wild type and A20
myel-KO mice, and was slightly lower in
A20
myel-KO mice (data not shown). Next, we measured pulmonary
viral titers at 4, 7 and 10 days post infection. No differences in viral
titers were observed in A20
myel-KO mice versus wild type mice at
day 4 and 7 post infection. However, after 10 days, almost no virus
could be detected in the lungs of A20
myel-KO mice while abundant
infectious viral particles could still be isolated from lungs of all wild
type mice (figure 3B). This indicates that loss of A20 in myeloid
cells does not affect early viral replication but contributes to viral
clearance at later stages during infection.
Figure 3. A20 deficiency in myeloid cells protects against IAV lung infection. A20
myel-WT and A20
myel-KO mice were infected intranasally with
a sublethal dose of IAV and weight loss was monitored (A). At day 4, 7 and 10 post infection (p.i.) viral titers in the lung were measured and expressed
as mean TCID50 (B). The dashed line represents the detection limit. ND, not detectable. BAL was isolated from IAV infected mice at 4, 7 and 10 days p.i.
and KC, MIP-2, MCP-1, IL-6 and IFNa protein levels were analyzed by ELISA and multiplexing technologies (C). Absolute numbers of resident alveolar
macrophages, neutrophils and monocytes in BAL were analyzed by flow cytometry at 4, 7 and 10 days p.i. (D). Numbers are averages +/2 SEM of at
least 5 mice per group and are representative of 2 independent experiments. *p,0.05; **p,0.01.
doi:10.1371/journal.ppat.1002570.g003
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PLoS Pathogens | www.plospathogens.org 5 March 2012 | Volume 8 | Issue 3 | e1002570To verify if A20 deficiency in myeloid cells affects IAV-induced
gene expression in the lung, we analyzed the levels of several
chemokines and cytokines in the bronchoalveolar lavage (BAL) at
day 4, 7 and day 10 following infection. Levels of KC and MIP-2
chemokines, as well as IL-6 were significantly higher at day 7 p.i.
in BAL from IAV infected A20
myel-KO mice compared to IAV
infected wild type mice (figure 3C). Unlike our observations with in
vitro stimulated primary macrophages we could not detect a
significant increase in MCP-1 or IFNa production in the lungs of
A20
myel-KO animals (figure 3C). KC is the murine orthologue of
IL-8 and serves together with MIP-2 as a chemoattractant for
neutrophils, while MCP-1 is mainly known as a chemoattractant
for monocytes, which eventually develop into macrophages upon
entering the alveolar lumen [60]. Consistent with the higher KC
and MIP-2 levels in A20
myel-KO mice, the number of neutrophils
(CD11b
+ Ly6C
+ Ly6G
+ F4/80
2) that were recruited in the
bronchoalveolar spaces upon IAV infection was clearly higher
throughout infection in A20
myel-KO mice compared to control
animals (figure 3D). Although we could detect a significant
increase in monocyte (CD11b
+ Ly6C
+) recruitment at day 4 post
infection, this was not evident at later time points after infection
(figure 3D), which is consistent with the equal expression of MCP-
1 in both groups of mice. The number of resident alveolar
macrophages (autofluorescent
+ CD11c
+ F4/80
+ CD11b
2) was
also elevated in A20
myel-KO mice but did not differ significantly
between IAV infected or mock infected mice (figure 3D).
Elimination of IAV infected cells depends on the clonal expansion
of virus specific cytotoxic CD8
+ T cells (CTL) [61,62,63]. To test
whether A20 expression in myeloid cells regulates the antiviral
CTL response, total CD8
+ T cells and virus specific Granzyme B
(GrB) and IFNc expressing CD8
+ T cells were measured in BAL
and lung parenchyma of wild type and A20
myel-KO mice. A clear
increase in CD8
+ T cells could be detected at day 7 and 10 post
infection, but no differences were observed between A20
myel-KO
and wild type mice (figure S2A and figure S2C). Also, the number
of GrB and IFNc CD8
+ T cells as well as IFNc expression levels in
the lungs were not altered by the absence of A20 in myeloid cells
(figure S2A–C).
Protection against IAV infection is also provided by the
humoral immune response. To test whether loss of A20 in
myeloid cells affects B cell mediated immunity, we determined
hemagglutinin (HA) antibody titers in the serum of A20
myel-KO
and wild type littermates. However, no differences could be
detected between wild type and A20
myel-KO animals (figure
S2D), indicating that humoral immunity is not affected by A20
expression in myeloid cells. Together, these data suggest that
mechanisms other than adaptive immunity, such as an
increased innate immune response, characterized by an
increased influx of neutrophils and increased numbers of
alveolar macrophages, contribute to the better viral clearance
in A20
myel-KO mice.
It is generally believed that IAV-induced mortality is due to an
excessive proinflammatory response in the lung. We therefore
analyzed whether the increased proinflammatory cytokine pro-
duction and infiltration of proinflammatory cells in A20
myel-KO
mice affects mortality induced by intranasal infection with a lethal
dose of IAV X-47. Surprisingly, almost all A20
myel-KO mice
survived (10/11), while all control mice succumbed (0/11) within
16 days after infection (figure 4A). A20
myel-KO mice still showed
significant weight loss and lung damage (as reflected by increased
total protein concentration in the BAL; data not shown) during the
course of infection but were able to recover, in contrast to wild
type mice that succumbed (figure 4B). Similar to our observations
with sublethal IAV infection, pulmonary KC and MIP-2
production was stronger in A20
myel-KO animals compared to wild
type mice following lethal IAV infection (figure 4C), which
correlates with the increased numbers of neutrophils in the lungs
of these mice (figure 4C). Also levels of the proinflammatory
cytokines IL-6, TNF and IL-1b, which are often associated with
immunopathogenesis in humans [64], were increased in the lungs
of A20
myel-KO mice compared to control animals (figure 4C and
figure S3A). Again, MCP-1 production was not increased and
even lower in A20
myel-KO mice (figure 4C), and also monocyte
recruitment was not different between both groups of mice. We
could also not detect any differences in viral clearance or antiviral
adaptive immunity at 6 h post infection (figure S3B–F). Collec-
tively these data indicate that A20 deficiency in myeloid cells is
associated with an increased innate immune response and
protection against a lethal IAV infection.
Discussion
In the present study we have investigated the contribution of
A20 expression in myeloid cells in the innate immune response to
IAV lung infection. In the pulmonary environment, macrophages
populate both lung parenchyma and the alveolar lumen where
they are referred to as alveolar macrophages. Under naı ¨ve
conditions, alveolar macrophages exert important immunomodu-
latory functions [65,66]. However, alveolar macrophages are also
crucial in the innate immune response against IAV as they are one
of the first cells that encounter infectious IAV particles [67,68].
They are an important source of proinflammatory cytokines and
chemokines that attract innate immune cells to the lung during the
primary phase of infection [69], and they are the primary
producers of type I IFNs [70]. Alveolar macrophages are also
known to phagocytose virus infected apoptotic cells and antibody
coated viral particles, further contributing to viral clearance. We
could show that BMDM or alveolar macrophages derived from
A20
myel-KO mice express higher amounts of chemokines, cytokines
and type I IFNs compared to wild type mice in response to in vitro
infection. Similarly, in vivo infection with IAV resulted in higher
levels of primarily neutrophil attracting chemokines such as KC
and MIP-2 and several proinflammatory cytokines such as IL-6,
TNF and IL-1b in the lungs of A20
myel-KO mice compared to wild
type mice. This was associated with a selective enhancement of
neutrophil recruitment to the bronchoalveolar compartment, and
resulted in improved viral clearance later on during infection.
Although the role of neutrophils during viral infection is still under
debate, recent evidence supports a protective function of these cells
during IAV infection [71,72]. MCP-1 levels were not affected by
the absence of A20 in myeloid cells, which is consistent with the
notion that airway epithelial cells are the primary source of MCP-
1 production during IAV infection [73]. Mice deficient for the
MCP-1 receptor CCR2, which is expressed on a subset of
circulating monocytes, are protected against IAV infection and
display reduced signs of immunopathology [74–76]. During IAV
infection these monocytes develop into inflammatory dendritic
cells or proinflammatory macrophages [77] and are considered
major contributors to IAV-induced immunopathology [78].
A20
myel-KO mice were protected against a lethal IAV infection,
which is rather surprising since an excessive proinflammatory
cytokine response and an excessive influx of inflammatory cells is
generally believed to be associated with increased lethality [64,79].
However, the selective effect of A20 deficiency on neutrophil
recruitment, without altering inflammatory monocyte (Ly6C
+
CD11b
+) recruitment, further support the idea that monocytes and
not neutrophils are major contributors to IAV-associated immu-
nopathology and lethality [78].
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PLoS Pathogens | www.plospathogens.org 6 March 2012 | Volume 8 | Issue 3 | e1002570We show that A20 deficient BMDM display enhanced NF-kB
and IRF3 activation in response to RIG-I stimulation by synthetic
LMW double stranded RNA. RIG-I has previously been shown to
play a key role in the innate immune response to IAV [13],
suggesting that the increased immune response of A20
myel-KO mice
to IAV lung infection reflects enhanced RIG-I signaling. We
propose that A20 inhibits IAV-induced proinflammatory gene
expression (as shown in our manuscript for TNF, IL-6, KC, MIP-
2, and IFNb) by negatively regulating NF-kB and IRF3 activation,
which are the major pathways controlling these genes. However,
this does not exclude an additional effect of A20 on other signaling
pathways that may contribute to proinflammatory gene expres-
sion. A20 is believed to exert its NF-kB and IRF3 inhibitory
functions by modulating the ubiquitination status of different
signaling proteins [80]. In this context, it was recently shown that
A20 cooperates with the ubiquitin-binding proteins TAX1BP1
and ABIN1 to to disrupt the TRAF3-TBK1-IKKe complex,
thereby negatively affecting K63-polyubiquitination of TBK1 and
IKKe, and their ability to activity IRF3 [81,82]. Whether similar
mechanisms are involved in the regulation of RIG-I induced NF-
kB activation is still unclear. So far we were unable to clearly
detect ubiquitination of TBK1 and IKKe in primary macrophag-
es, preventing us from studying the effect of A20 deficiency on
their ubiquitination status. It cannot be excluded however that
A20 also targets other substrates that mediate NF-kB and IRF3
activation in myeloid cells. The identification of these substrates
Figure 4. A20 deficiency in myeloid cells protects against lethal IAV infection. A20
myel-WT (n=11) and A20
myel-KO (n=11) mice were
intranasally infected with a lethal dose of IAV and survival (p,0.001) (A) and weight loss +/2 SEM (B) was monitored for respectively 21 and 15 days
p.i. BAL fluid was collected from wild type (A20
myel-WT) and A20
myel-KO mice 6 days following infection with a lethal dose IAV and KC, MIP-2, MCP-1, IL-
6 and IFNa protein levels were determined (C). Absolute numbers of alveolar macrophages, neutrophils and monocytes in BAL were analyzed by flow
cytometry at 6 days p.i. (D). Numbers are averages +/2 SEM of at least 5 mice per group. Data are representative of 2 independent experiments.
*p,0.05; **p,0.01, ***p,0.001.
doi:10.1371/journal.ppat.1002570.g004
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other deubiquitinating enzymes (DUBs), such as DUBA [28],
CYLD [29,30], OTUB1/2 [31], and A20 [49–52] have been
shown to negatively regulate RIG-I signaling to NF-kB and IRF-3,
implicating possible redundancy. However, evidence so far was
limited to in vitro data and was obtained under non-physiological
conditions. The clear protective phenotype of A20
myel-KO mice
that we here describe indicates that A20 expression in myeloid
cells is a central gatekeeper of RIG-I induced signaling in response
to IAV infection and that other DUBs cannot substitute for A20
deficiency under physiological conditions. If A20 has a similar
non-redundant role in other cell types that are implicated in the
response to IAV, such as lung epithelial cells, remains to be
investigated.
Understanding and controlling the activation of innate
antiviral immune responses is an important step toward novel
therapies. About a fifth of world’s population is infected by IAV
annually, leading to high morbidity and mortality, particularly in
infants, the elderly and the immunocompromised. The high
mutation rate of IAV turns all attempts of vaccine and antiviral
design into a never ending battle. In recent years, RNA
interference, triggered by synthetic short interfering RNA
(siRNA), has rapidly evolved as a potent antiviral regimen.
Properly designed siRNAs have been shown to function as potent
inhibitors of influenza virus replication. Although specificity and
tissue delivery remain major bottlenecks in the clinical applica-
tions of RNAi in general, intranasal application of siRNA against
respiratory viruses including, but not limited to influenza virus,
has experienced significant success and optimism [83]. Our
results suggest that not only siRNA targeting IAV components,
but boosting the antiviral immune response by intranasal
administration of siRNA against A20 might be a valid therapeutic
approach. Also small compound inhibitors of A20 might be an
interesting alternative. Finally, similar targeting of A20 might be
of interest in the battle against other viral infections including
RSV and SARS coronavirus.
Materials and Methods
Ethics statement
All experiments on mice were conducted according to the
national (Belgian Law 14/08/1986 and 22/12/2003, Belgian
Royal Decree 06/04/2010) and European (EU Directives 2010/
63/EU, 86/609/EEG) animal regulations. Animal protocols were
approved by the ethics committee of Ghent University (permit
number LA1400091, approval ID 2010/001). All efforts were
made to ameliorate suffering of animals. Mice were anesthetized
by intraperitoneal (i.p.) injection of a mixture of ketamine (12 mg/
kg) and xylazine (60 mg/kg).
Mice
A20
fl/fl mice were generated as previously described [56]. A20
fl/fl
mice were crossed with LysM-Cre mice [84] (provided by I. Fo ¨rster,
Institute of Genetics, University of Cologne, Germany) to generate
A20
fl/fl LysMCre transgenes and are described in detail elsewhere
[48]. Mice were housed in individually ventilated cages at the VIB
Department of Molecular Biomedical Research in specific patho-
gen-free animal facilities. Influenza infections were performed on
age- (between 7 and 9 weeks old) and sex-matched littermates.
A20
fl/fl LysM-Cre animals were backcrossed three times to the
C57Bl/6 background. A20
fl/fl mice expressing or lacking the LysM-
Cre transgene were termed A20
myel-KO and wild type (A20
myel-WT)
respectively.
Viral infection and determination of viral titers
Mouse adapted IAV X-47 (H3N2; PR86A/Victoria/3/75) was
propagated in MDCK cells. For viral inoculation, mice were
anesthetized by i.p. injection with ketamine (12 mg/kg) and
xylazine (60 mg/kg) and 50 ml X-47 diluted in PBS was
administered intranasally. For lethal and sublethal infection, mice
received respectively 2-LD50 or 0.05-LD50 X-47. To determine
pulmonary viral titers, median tissue culture infectious dose
(TCID50) was measured as follows: lungs were homogenized with
a Polytron homogenizer (Kinematica) in PBS. Eight-fold serial
dilutions of lung homogenates were incubated on MDCK cells for
5 days in DMEM supplemented with trypsin (1 mg/ml), 2 mM L-
glutamine, 0.4 mM sodium pyruvate and antibiotics. For read-out,
0.5% chicken red blood cells (RBC) were added and end-point
dilution of hemagglutination was monitored. TCID50 titers were
then calculated according to the method of Reed and Muench
[85].
Determination of HAI (hemagglutination inhibition) titers
To determine the HAI titers in infected mice, sera of these were
treated with receptor-destroying enzyme (RDE/Cholera filtrate;
Sigma) to remove sialic acids from serum proteins capable of
aspecific inhibition of agglutination. After incubation overnight at
37uC, the RDE was inactivated by addition of 0.75% sodium
citrate in PBS and heating to 56uC for 30 min. To remove sialic
acid binding proteins, sera were cleared with 1/10 volume 50%
chicken RBC. Titration was done by incubating a two-fold
dilution series of sera with 4 HA units of X-47 virus for 1 hour at
room temperature in 96-well U-bottom plates. Finally, an equal
volume of 0.5% chicken RBC was added and titers were read
30 min later. Negative controls included PBS instead of immune
serum (agglutination control) or PR8 instead of X-47 virus (control
for agglutination effect of sera); as positive control, serum from a
mouse infected twice with a sublethal dose of X-47 was used.
In vivo intracellular GrB and IFNc staining of activated
CD8+ T cells
Granzyme B (GrB) and IFNc expressing CD8
+ T cells were
determined by treating the mice intranasally with 50 mg Brefeldin
A (Sigma) as previously described [86]. 6 h later, BAL and lungs
were isolated and single cell suspensions were prepared from the
lung in the presence of 3 mg/ml Brefeldin A. Cells were stained,
fixed and permeabilized (Cytofix/Cytoperm, BD Biosciences)
according to the manufacturer’s instructions. Activated CD8
+ T
cells were analyzed by flow cytometry based on CD62
lo CD3
+ and
CD8
+ expression. Live/Dead fixable aqua dead cell stain kit
(Molecular Probes) was used to discriminate live from dead cells.
Cells and transfection
HEK293T and MDCK cells were grown in DMEM (Gibco)
supplemented with 10% FCS, 2 mM L-glutamine, 0.4 mM
sodium pyruvate and antibiotics. HEK293T cells were transfected
using the calcium phosphate precipitate transfection method with
specific expression vectors (pCAGGS-E-hA20 (LMBP 3778),
pCAGGS-E-RIG-I-CARD (LMBP 6517), pEF-HA-IRF-7 (kindly
provided by T. Taniguchi, Graduate School of Medicine and
Faculty of Medicine, University of Tokyo)), NF-kB, IRF3, IRF7
reporter plasmids (respectively pConLuc (LMBP3248), pISRE-luc
(LMBP4011), pGL3-IFNa4-luc (kindly provided by J. Hiscott,
McGill University, Montreal, Quebec, Canada), and pACTbeta-
gal (LMBP4341) for transfection efficiency normalization. Details
of plasmids are presented along with detailed sequence maps at the
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For the generation of BMDM, bone marrow cells were cultured
7 days in RPMI 1640 (Gibco) supplemented with 10% FCS,
2 mM L-glutamine, 0.4 mM sodium pyruvate, antibiotics and
40 ng/ml recombinant M-CSF. BMDM were of $95% purity as
measured by flow cytometry using F4/80 and CD11b specific
antibodies. For the isolation of alveolar macrophages, the trachea
was canulated and the lung was flushed 4 times with HBSS
containing 1 mM EDTA. Alveolar macrophages were cultured in
RPMI 1640 (Gibco) supplemented with 1% FCS, 2 mM L-
glutamine, 0.4 mM sodium pyruvate and antibiotics.
Western blotting
For total lysates, cells were lysed at 4uC for 15 min in lysis
buffer (200 mM NaCl, 1% NP-40, 10 mM Tris-HCl pH 7.5,
5 mM EDTA, 2 mM DTT) supplemented with protease and
phosphatase inhibitors. Nuclear and cytoplasmic lysates were
prepared by resuspending cells in B1 (10 mM Hepes pH 7.5,
10 mM KCl, 1 mM MgCl2,5 %g l y c e r o l ,0 . 5m ME D T Aa n d
0.1 mM EGTA supplemented with protease and phosphatase
inhibitors) for 15 min at 4uC. Next, NP-40 detergent was added
to a final concentration of 0.65% and cells were centrifuged at
500 g for 5 min. The nuclear fraction containing pellet was
lyzed in B2 (20 mM Hepes pH 7.5, 1% NP-40, 400 mM NaCl,
10 mM KCl, 1 mM MgCl2, 20% glycerol, 0.5 mM EDTA and
0.1 mM EGTA supplemented with protease and phosphatase
inhibitors) for 15 min at 4uC. The lysates were subsequently
separated by SDS-PAGE and analyzed by western blotting and
ECL detection (Perkin Elmer Life Sciences). Immunoblots were
revealed with anti-A20, anti-IkBa, anti-p65, and anti-histon H1
(Santa Cruz), anti-IRF3 (Invitrogen), anti-phospho-IRF3 and
anti-phospho-IkBa (Cell Signaling) and anti-actin (MP Bio-
medicals). The density of the bands was quantified (fold
induction) with the ImageJ (http://rsbweb.nih.gov/ij) Gel
analyzer tool. All intensities were calculated relative to the first
lane (=time 0).
Flow cytometry
Lungs were dissected and incubated with collagenase type IV
(1 mg/ml; Sigma) and DNAse (100 U/ml; Roche) at 37uC for
30 min. Subsequently, samples were filtered through a 70 mm and
40 mm nylon mesh. For the preparation of BAL, trachea were
canulated and airway lumen was flushed 4 times with HBSS with
1 mM EDTA. Cells were stained with monoclonal antibodies
directed against MHC-II (I-A/I-E) FITC (M5/114.15.2), CD11c
PerCP-Cy5.5 (N418), F4/80 APC (BM8), CD62L PE (MEL-14),
Granzyme B FITC (NGZB) from eBiosciences and CD3
Molecular Complex Horizon v450 (17A2), Ly6C Horizon v450
(AL-21), Ly6G PE (1A8), CD11b APC-Cy7 (M1/70), CD8a
PerCP (53-6.7), IFNc Alexa 647 (XMG1.2) and CD16/32 (2.4G2)
from BD Pharmingen. Samples were acquired on a LSRII
Cytometer and analyzed using FACSDiva software (BD Biosci-
ences). Propidium iodide was used to discriminate between live
and dead cells.
Cytokine quantification
For TNF ELISA, 96-well plates were coated with TNF coating
(TN3-19, eBioscience) and detection (R4-6A2, eBioscience)
antibodies. IFNa and IFNb protein levels were determined with
an ELISA kit (PBL Biomedical Laboratories). For IFNc ELISA,
96-well plates were coated with IFNc coating (XMG1.2) and
detection (R4-6A2) antibodies (eBiosciences). Detection of MCP-1,
KC, TNF, IL-1b and IL-6 in BAL fluid was performed using
Bioplex (BioRad) technology according to the manufacturer’s
instructions. Milliplex technology (Millipore) was used for the
detection of MIP-2 in BAL fluid.
RNA isolation, cDNA synthesis and qPCR
Total RNA was extracted using Aurum Total RNA mini kit
(BioRad) and reverse transcribed into cDNA with iScript cDNA
synthesis kit (BioRad) according to the manufacturer’s instructions.
qPCR was performed by using SYBR Green I master mix I
(Roche) in the Lightcycler 480 detection system (Roche) with the
following primers: HPRT: 59-AGTGTTGGATACAGGCCA-
GAC-39 and 59CGTGATTCAAATCCCTGAAGT-39; IL-6: 59-
GAGGATACCACTCCCAACAGACC-39 and 59-AAGTGCAT-
CATCGTTGTTCATACA-39; IFNb:5 9-TCAGAATGAGTG-
GTGGTTGC-39 and 59-GACCTTTCAAATGCAGTAGAT-
TCA-39; A20: 59-AAACCAATGGTGATGGAAACTG-39 and
59-GTTGTCCCATTCGTCATTCC-39; CCL2: 59-TTAAAAA-
CCTGGATCGGAACCAA-39 and 59-GCATTAGCTTCAGA-
TTTACGGGT-39; CXCL1: 59-GAGCCTCTAACCAGTTCC-
AG-39 and 59-TGAGTGTGGCTATGACTTCG-39 and IFNa4:
59-TGATGAGCTACTACTGGTCAGC-39 and 59-GATCTCT-
TAGCACAAGGATGGC-39. Primers were designed with Perl-
Primer (http://perlprimer.sourceforge.net). Quantification was
performed using the comparative CT method (DDCT). Results
are expressed relative to HPRT values.
Statistics
Results are expressed as the mean 6 SEM. Statistical
significance between groups was assessed using two-way ANOVA.
The differences for in vivo experiments (at least 5 mice per group)
were calculated using the Mann-Whitney U-test for unpaired data.
Statistical significance of differences between survival rates was
analyzed by comparing Kaplan-Meier curves using the log-rank
test (GraphPad Prism version 5, GraphPad, San Diego, CA).
Supporting Information
Figure S1 A20 deficient alveolar macrophages are
hyperresponsive to IAV infection. Alveolar macrophages
isolated from A20
myel-KO and wild type (A20
myel-WT) mice were
mock treated or infected with IAV (moi 1) for 18 hours. TNF,
MCP-1 (ccl2), KC (cxcl1) and IFNa4 mRNA expression was
determined by qPCR (A). Cell culture supernatant was analyzed
for TNF, MCP-1 and KC protein levels by ELISA and
multiplexing technologies (B). Error bars represent mean values
(+/2 SEM) of 2–3 samples. Results are representative for 2
independent experiments. *p,0.05; **p,0.01; ***p,0.001.
(TIF)
Figure S2 Adaptive immunity is not altered by the
absence of A20 in myeloid cells following sublethal IAV
infection. Wild type (A20
myel-WT) and A20
myel-KO mice were
infected intranasally with a sublethal dose of IAV. BAL was
isolated from IAV infected mice at 4, 7 and 10 days p.i. and
analyzed for total CD8
+ T cells, Granzyme B (GrB) and IFNc
expressing CD8
+ T cells (A) and IFNc protein levels (B). Total
CD8
+ T cells, GrB and IFNc expressing CD8
+ T cells in the lung
parenchyma were also determined by flow cytometry (C). Virus
specific antibody titers in serum at 4, 7 and 10 days p.i. were
determined via a hemagglutination inhibition (HAI) assay. The
dashed line depicts the detection limit of the assay (D). Numbers
are averages +/2 SEM of at least 5 mice per group and are
representative of 2 independent experiments.
(TIF)
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absence of A20 in myeloid cells following lethal IAV
infection. Wild type (A20
myel-WT) and A20
myel-KO mice were
infected intranasally with a lethal dose of IAV. 6 days p.i. mice
were sacrificed and analyzed. (A) TNF and IL-1b protein levels
in BAL fluid were measured by ELISA and multiplexing
technologies. (B) Viral titers in the lung were measured and
expressed as mean TCID50. The dashed line represents the
detection limit. (C) Total CD8
+,G r Ba n dI F N c expressing T
cells in BAL fluid were measured using flow cytometry. (D) IFNc
protein levels in BAL fluid were measured by ELISA. (E) Total
CD8
+,G r Ba n dI F N c expressing T cells in lung parenchyma
were measured using flow cytometry. (F) Virus specific antibody
titers in serum were determined via a hemagglutination
inhibition (HAI) assay. The dashed line depicts the detection
limit. Numbers are averages +/2 SEM of at least 5 mice per
group. *p,0.05; **p,0.01.
(TIF)
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